Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688473 | 0.81 | TYRO3 (0.31) | — | |
| SCHEMBL6910408 | 0.74 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL12345550 | 0.74 | RPS6KA3 (0.58) | RPS6KA3 | |
| SCHEMBL16178560 | 0.74 | RPS6KA3 (0.58) | RPS6KA3 | |
| SCHEMBL4085053 | 0.72 | RPS6KA3 (0.41) | RPS6KA3 | |
| SCHEMBL16178606 | 0.71 | ELANE (0.35) | ALDH1A1 | |
| SCHEMBL5937055 | 0.70 | PLK1 (0.40) | — | |
| SCHEMBL24603058 | 0.69 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL15987137 | 0.69 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL1688562 | 0.69 | SMN1; SMN2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140315911-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140315911-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315911-A1 | DIHYDROPTERIDINONES | DHPS, DHODH, HYPK | RPS6KA3 62/4885PDE2A 4764/4885ADORA2A 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.